344 related articles for article (PubMed ID: 32298469)
21. Recent advances in understanding and treating immunoglobulin light chain amyloidosis.
Badar T; D'Souza A; Hari P
F1000Res; 2018; 7():. PubMed ID: 30228867
[TBL] [Abstract][Full Text] [Related]
22. Modified High-Dose Melphalan and Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis.
Nguyen VP; Landau H; Quillen K; Brauneis D; Shelton AC; Mendelson L; Rahman H; Sloan JM; Sarosiek S; Sanchorawala V
Biol Blood Marrow Transplant; 2018 Sep; 24(9):1823-1827. PubMed ID: 29933072
[TBL] [Abstract][Full Text] [Related]
23. Fibril-directed Therapies in Systemic Light Chain AL Amyloidosis.
Bhutani D; Leng S; Lentzsch S
Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):555-559. PubMed ID: 31262668
[TBL] [Abstract][Full Text] [Related]
24. Systemic immunoglobulin light chain amyloidosis.
Merlini G; Dispenzieri A; Sanchorawala V; Schönland SO; Palladini G; Hawkins PN; Gertz MA
Nat Rev Dis Primers; 2018 Oct; 4(1):38. PubMed ID: 30361521
[TBL] [Abstract][Full Text] [Related]
25. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
26. Management of AL amyloidosis in 2020.
Palladini G; Milani P; Merlini G
Blood; 2020 Dec; 136(23):2620-2627. PubMed ID: 33270858
[TBL] [Abstract][Full Text] [Related]
27. [Heart transplantation and the subsequent treatment of AL amyloidosis].
Adam Z; Krejčí J; Krejčí M; Němec P; Spinarová L; Zampachová V; Cermáková Z; Pika T; Pour L; Kořístek Z; Tomíška M; Szturz P; Král Z; Mayer J
Vnitr Lek; 2013 Feb; 59(2):136-47. PubMed ID: 23461404
[TBL] [Abstract][Full Text] [Related]
28. Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021.
Hasib Sidiqi M; Gertz MA
Blood Cancer J; 2021 May; 11(5):90. PubMed ID: 33993188
[TBL] [Abstract][Full Text] [Related]
29. Recent Advances in the Diagnosis, Risk Stratification, and Management of Systemic Light-Chain Amyloidosis.
Vaxman I; Gertz M
Acta Haematol; 2019; 141(2):93-106. PubMed ID: 30650422
[TBL] [Abstract][Full Text] [Related]
30. A safety review of drug treatments for patients with systemic immunoglobulin light chain (AL) amyloidosis.
Nuvolone M; Basset M; Palladini G
Expert Opin Drug Saf; 2021 Apr; 20(4):411-426. PubMed ID: 33583294
[TBL] [Abstract][Full Text] [Related]
31. How we treat systemic light-chain amyloidosis.
Chaulagain CP; Comenzo RL
Clin Adv Hematol Oncol; 2015 May; 13(5):315-24. PubMed ID: 26352777
[TBL] [Abstract][Full Text] [Related]
32. Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018.
Gertz MA
Blood Cancer J; 2018 May; 8(5):44. PubMed ID: 29795248
[TBL] [Abstract][Full Text] [Related]
33. Bispecific Antibodies and Antibody-Drug Conjugates for Cancer Therapy: Technological Considerations.
Shim H
Biomolecules; 2020 Feb; 10(3):. PubMed ID: 32111076
[TBL] [Abstract][Full Text] [Related]
34. Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatment.
Gertz MA
Am J Hematol; 2018 Sep; 93(9):1169-1180. PubMed ID: 30040145
[TBL] [Abstract][Full Text] [Related]
35. Monoclonal antibodies in the treatment of AL amyloidosis: co-targetting the plasma cell clone and amyloid deposits.
Popkova T; Hajek R; Jelinek T
Br J Haematol; 2020 Apr; 189(2):228-238. PubMed ID: 32072615
[TBL] [Abstract][Full Text] [Related]
36. Bringing Together the Power of T Cell Receptor Mimic and Bispecific Antibodies for Cancer Immunotherapy: Still a Long Way to Go.
Shivarov V; Blazhev G
Monoclon Antib Immunodiagn Immunother; 2021 Apr; 40(2):81-85. PubMed ID: 33900820
[TBL] [Abstract][Full Text] [Related]
37. High-Dose Melphalan and Stem Cell Transplantation in Patients on Dialysis Due to Immunoglobulin Light-Chain Amyloidosis and Monoclonal Immunoglobulin Deposition Disease.
Batalini F; Econimo L; Quillen K; Sloan JM; Sarosiek S; Brauneis D; Havasi A; Stern L; Dember LM; Sanchorawala V
Biol Blood Marrow Transplant; 2018 Jan; 24(1):127-132. PubMed ID: 28865972
[TBL] [Abstract][Full Text] [Related]
38. Novel monoclonal antibodies: A really specific therapy for light chain amyloidosis.
Del Giudice ML; Galimberti S; Buda G
Hematol Oncol; 2024 May; 42(3):e3270. PubMed ID: 38590272
[TBL] [Abstract][Full Text] [Related]
39. Updates in the Diagnosis and Management of AL Amyloidosis.
Cook J; Muchtar E; Warsame R
Curr Hematol Malig Rep; 2020 Jun; 15(3):155-167. PubMed ID: 32394186
[TBL] [Abstract][Full Text] [Related]
40. Use of novel therapies in the treatment of light chain amyloidosis.
Varga C; Titus SE; Toskic D; Comenzo RL
Blood Rev; 2019 Sep; 37():100581. PubMed ID: 31167719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
